Jordana Joy, Associate Editor

The study found that 17.4% of Medicare patients needed subspecialized procedures relative to 5.6% of surgeons practicing in rural areas between 2012 and 2022.

Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, weighs in on what's on the horizon for pediatric myopia management, and provides some tips for diving into scleral lens fitting.

Prominent legislation includes the Corporate Transparency Act and last year's spending bill provision that was struck down.

Shan Lin, MD, outlines a new generation of minimally invasive glaucoma surgeries (MIGS) at Glaucoma 360.

Steven T. Reed, OD, talks Optometry's Meeting and public-facing initiatives that optometrists can take advantage of.

The study evaluated 13 teenagers and young adults who had high myopia (−6.50 to −9.25 D).

For Ashley Wallace Tucker, OD, FAAO, FSLS, Dipl ABO, last week's conference gives a unique opportunity for optometrists and ophthalmologists to collaborate.

Steven T. Reed, OD, American Optometric Association's president, overviews the 2024 highlights and how the organization plans to extend success into 2025.

A total of 150 placements are for aspiring optometrists to shadow SpaMedica’s clinical teams and in-house optometrists as they treat patients.

Ashley Mills, The Vision Council CEO, outlines new additions to the show that are unveiling what is to come in terms of fashion, technology, and patient care.

Catch up on the top stories in optometry during the week of February 10-February 14.

According to a news release from the company, the VR platform “disrupt[s] traditional diagnostic methods by offering an untethered, all-in-one diagnostic solution that includes a variety of tests such as visual field, progression analysis, color sensitivity, and now visual acuity testing.”

The Vision Council CEO Ashley Mills overviews what is new and exciting at this year's show, running from February 19-22 in Orlando, Florida, and provides a free registration code for those still looking to register.

Practice Compliance Solutions, CodeSAFEPLUS, Practice Resource Management, and EyeCode Education have formed Practice Performance Partners.

Walline, OD, PhD, FAAO, outlines how to predict myopia progression and delay its onset in an exclusive interview with Optometry Times.

Toronto-based Cellview currently designs and manufactures highly performant diagnostic imaging instruments that leverage internal R&D expertise, according to a news release.

The review “illuminates the pressing need for further research into this sight-threatening condition, particularly prospective, randomized, or well controlled cohort studies,” according to its authors.

Jeffrey Walline, OD, PhD, FAAO, overviews a presentation he gave on the Bifocal Lenses in Nearsighted Kids 2 (BLINK2) cohort study at the Collaborative Community on Ophthalmic Innovation (CCOI).

The device was created in collaboration with SlitLED and featuring AutoAquire, RemotePilot, and Multi-Slit views.

Walline, OD, PhD, FAAO, states that the best way to learn the benefits of artificial intelligence for your practice is to stay on top of continuing education attendance.

Now, the VTO platform features 3 different offerings, 2 which are new and 1 which has been updated, according to the company.

The CREST Registry study reported on the safety and effectiveness outcomes of microinvasive cyclodialysis clef formation with the CycloPen system, followed by scleral reinforcement with AlloFlo Bio-Tissue implantation, according to Iantrek.

The announcement comes after a request was made by the Canadian Investment Regulatory Organization (CIRO) to explore the possibility of a sale.

Catch up on what happened in optometry during the week of February 3-February 7.

Jeffrey Walline, OD, PhD, FAAO, gives an overview of the AAO's 2024 and what to expect in 2025 and beyond.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The company sits at spot 43 for “its outstanding performance in areas including unit growth, financial strength and stability, and brand power."

All QLS-111 concentrations and dose regimens in both Osprey and Apteryx trials “demonstrated excellent safety and tolerability,” according to the company.

The goal of the agreement is to advance Eleva’s current programs into mid- and late-stage clinical development.

C.Rex is the only MGIS technology on the market that allows for fully titratable 180-360 comprehensive intervention.